FMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fresenius Medical Care AG is not a strong buy for a beginner investor with a long-term horizon at the moment. While the company has shown strong financial performance in the latest quarter, the technical indicators are bearish, analysts have lowered price targets, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. Holding the stock or waiting for a better entry point would be more prudent.
The technical indicators suggest a bearish trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 49.817, and the moving averages indicate a bearish setup (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 22.43, with resistance at 23.117 and support at 21.742.
The company reported strong financial performance in Q4 2025, with revenue up 8.82% YoY, net income up 433.64% YoY, and EPS up 454.17% YoY. Gross margin also improved by 9.65%.
Analysts have consistently lowered price targets, citing headwinds such as sluggish treatment volume growth, potential regulatory challenges, and cost pressures. The technical indicators are bearish, and there are no recent news or significant trading trends to support a bullish sentiment.
In Q4 2025, Fresenius Medical Care AG demonstrated strong financial growth. Revenue increased by 8.82% YoY to $5.9 billion, net income surged by 433.64% YoY to $380.73 million, and EPS rose by 454.17% YoY to 1.33. Gross margin improved to 27.39%, up 9.65% YoY.
Analysts have lowered price targets multiple times in recent months. Deutsche Bank reduced its target to EUR 42 from EUR 44 and maintains a Hold rating, while Morgan Stanley lowered its target to EUR 34 from EUR 36 with an Underweight rating. Goldman Sachs downgraded the stock to Neutral from Buy, citing several headwinds for fiscal 2026.
